Allied Market Research

Preimplantation Genetic Testing Market Analysis 2023


Portland, OR -- (SBWIRE) -- 09/18/2017 -- Preimplantation genetic testing is performed prior to implantation that assists in the diagnosis of genetic defects present within the embryos. Preimplantation genetic testing helps analyze the genetic profile of embryos, which helps avoid selective pregnancy termination. In this process, a cell from an IVF embryo that is to be tested is removed before transferring the embryo to the uterus. The removed cell is tested for a specific genetic condition (for instance, cystic fibrosis).

Access the full summary at :

The key factors that drive the market growth include technological advancements in the field of genetic analysis and high risk of chromosomal abnormalities with increased maternal age. In addition, factors such as infertility issues among men and women also fuel the market growth. However, high costs associated with preimplantation genetic testing and unfavorable government regulations restrain the market growth. Increasing awareness about preimplantation genetic testing and growing medical tourism will offer lucrative opportunities for the market growth.

Get PDF Brochure of this report:

The key players of the market included in the report are Illumina, Inc., Thermo Fisher Scientific Inc., Agilent Technologies Inc., PerkinElmer Inc., Coopersurgical, Inc., Abbott Laboratories, Natera, Inc., Oxford Gene Technology, Yikon Genomics, and SciGene Corporation.

Key Benefits

-The study provides an in-depth analysis of the global preimplantation genetic testing market, with current trends and future estimations to elucidate imminent investment pockets.

-It presents a quantitative analysis from 2016 to 2023 to enable stakeholders to capitalize on prevailing market opportunities.

-Extensive analysis of the market by product elucidates various forms of available preimplantation genetic testing methods.

Early buyers will receive 20% customization on this report